Cardio Diagnostics Holdings, Inc.(CDIO)Earnings, Financials & Key Ratios
CDIO•NASDAQ
$1.82
$49M mkt cap·Price updated May 6, 2026
AboutCardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.Show more
- Revenue$35K+104.5%
- EBITDA-$8M-13.4%
- Net Income-$8M
- EPS (Diluted)-9.30+53.0%
- Gross Margin100%
- EBITDA Margin-23185.82%+44.5%
- Operating Margin-23977.86%+43.5%
- Net Margin-24028.24%+51.1%
- ROE-133.96%+41.9%
- ROIC-222.66%+18.7%
- Debt/Equity0.10-76.2%
- Interest Coverage-448.81-41636.6%
CDIO Key Insights
Cardio Diagnostics Holdings, Inc. (CDIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CDIO Price & Volume
Cardio Diagnostics Holdings, Inc. (CDIO) stock price & volume — 10-year historical chart
Loading chart...
CDIO Growth Metrics
Cardio Diagnostics Holdings, Inc. (CDIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years238.32%
TTM-55.78%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM20.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-40.17%
Return on Capital
10 Years-318.86%
5 Years-318.86%
3 Years-158.4%
Last Year-122.98%
CDIO Recent Earnings
Cardio Diagnostics Holdings, Inc. (CDIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 1/12 qtrs (10%)
Q4 2025Latest
Nov 12, 2025EPS
$0.98
Est $1.80
+45.6%
Revenue
$2,855
Est $150,000
-98.1%
Q3 2025
Aug 14, 2025EPS
$0.97
Est $1.80
+46.1%
Revenue
$7,475
Est $75,000
-90.0%
Q2 2025
May 15, 2025EPS
$0.97
Est $1.80
+46.1%
Revenue
$940
Est $75,000
-98.7%
Q2 2025
Mar 20, 2025EPS
$0.01
Est $0.06
+83.3%
Revenue
$4,512
Est $25,000
-82.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 12, 2025 | $0.98vs $1.80+45.6% | $2,855vs $150,000-98.1% |
| Q3 2025 | Aug 14, 2025 | $0.97vs $1.80+46.1% | $7,475vs $75,000-90.0% |
| Q2 2025 | May 15, 2025 | $0.97vs $1.80+46.1% | $940vs $75,000-98.7% |
| Q2 2025 | Mar 20, 2025 | $0.01vs $0.06+83.3% | $4,512vs $25,000-82.0% |
Based on last 12 quarters of dataView full earnings history →
CDIO Peer Comparison
Cardio Diagnostics Holdings, Inc. (CDIO) competitors in Diagnostics and Omics Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HLIO | 2.31B | 69.81 | 48.14 | 4.11% | 5.78% | 5.33% | 0.12 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 TMDX | 2.52B | 72.92 | 14.97 | 37.13% | 27.04% | 41.92% | 0.99 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 10.37% | 0.52 | |
 NEOG | 2B | 9.18 | -1.83 | -3.2% | -68.47% | -28.64% | 0.44 | |
 QDEL | 746.18M | 10.96 | -0.66 | -1.89% | -45.57% | -56.31% | 1.46 | |
 CERS | 518.96M | 2.59 | -31.59 | 14.35% | -4.41% | -15.18% | 1.49 |
Compare CDIO vs Peers
Cardio Diagnostics Holdings, Inc. (CDIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CDIO Income Statement
Cardio Diagnostics Holdings, Inc. (CDIO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 901 | 950 | 17.07K | 34.89K | 15.78K |
| Revenue Growth % | - | - | 5.44% | 1696.32% | 104.45% | -55.78% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 178.73K |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 901▲ 0% | 950▲ 5.4% | 17.07K▲ 1696.3% | 34.89K▲ 104.5% | -162.95K▲ 0% |
| Gross Margin % | - | 100% | 100% | 100% | 100% | -1032.5% |
| Gross Profit Growth % | - | - | 5.44% | 1696.32% | 104.45% | - |
| Operating Expenses | 609.16K | 621.35K | 4.55M | 7.26M | 8.4M | 6.37M |
| OpEx % of Revenue | - | 68962.15% | 478884.32% | 42540.43% | 24077.86% | - |
| Selling, General & Admin | 597K | 573.88K | 4.49M | 7.1M | 8.35M | 6.12M |
| SG&A % of Revenue | - | 63693.78% | 472942.42% | 41577.26% | 23937.82% | - |
| Research & Development | 1.5K | 31.47K | 40.45K | 145.18K | 29.13K | 204.29K |
| R&D % of Revenue | - | 3492.56% | 4257.68% | 850.76% | 83.48% | - |
| Other Operating Expenses | 10.67K | 16K | 16K | 19.18K | 19.74K | 50.79K |
| Operating Income | -609.16K▲ 0% | -620.45K▼ 1.9% | -4.55M▼ 633.1% | -7.24M▼ 59.2% | -8.37M▼ 15.5% | -6.54M▲ 0% |
| Operating Margin % | - | -68862.15% | -478784.32% | -42440.43% | -23977.86% | -41422.24% |
| Operating Income Growth % | - | -1.85% | -633.09% | -59.23% | -15.51% | - |
| EBITDA | -598.5K | -604.45K | -4.53M | -7.13M | -8.09M | -6.15M |
| EBITDA Margin % | - | -67086.35% | -477100.11% | -41786.34% | -23185.82% | -38961.06% |
| EBITDA Growth % | - | -0.99% | -649.85% | -57.33% | -13.44% | 24.5% |
| D&A (Non-Cash Add-back) | 10.67K | 16K | 16K | 111.62K | 276.35K | 388.42K |
| EBIT | -609.16K | -620.45K | -4.66M | -1.64M | -8.36M | -6.54M |
| Net Interest Income | 0 | 0 | 0 | -6.73M | -17.58K | -14.85K |
| Interest Income | 0 | 0 | 0 | 1.07K | 1.06K | 787 |
| Interest Expense | 0 | 0 | 0 | 6.74M | 18.64K | 15.64K |
| Other Income/Expense | 4K | 0 | -112.53K | -1.13M | -17.58K | -14.85K |
| Pretax Income | -605.16K▲ 0% | -620.45K▼ 2.5% | -4.66M▼ 651.2% | -8.38M▼ 79.7% | -8.38M▼ 0.1% | -6.55M▲ 0% |
| Pretax Margin % | - | -68862.15% | -490630% | -49087.81% | -24028.24% | -41516.33% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -605.16K▲ 0% | -620.45K▼ 2.5% | -4.66M▼ 651.2% | -8.38M▼ 79.7% | -8.38M▼ 0.1% | -6.55M▲ 0% |
| Net Margin % | - | -68862.15% | -490630% | -49087.81% | -24028.24% | -41516.33% |
| Net Income Growth % | - | -2.53% | -651.23% | -79.72% | -0.08% | 20.61% |
| Net Income (Continuing) | -605.16K | -620.45K | -4.66M | -8.38M | -8.38M | -6.55M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.06▲ 0% | -1.96▼ 2981.8% | -45.30▼ 2211.2% | -19.80▲ 56.3% | -9.30▲ 53.0% | -3.73▲ 0% |
| EPS Growth % | - | -2981.76% | -2211.22% | 56.29% | 53.03% | -40.17% |
| EPS (Basic) | -0.06 | -1.96 | -45.30 | -19.80 | -9.30 | - |
| Diluted Shares Outstanding | 9.52M | 317.16K | 3.09M | 422.84K | 26.89M | 1.76M |
| Basic Shares Outstanding | 9.52M | 317.16K | 3.09M | 422.84K | 26.89M | 1.76M |
| Dividend Payout Ratio | - | - | - | - | - | - |
CDIO Balance Sheet
Cardio Diagnostics Holdings, Inc. (CDIO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 245.92K | 803.51K | 5.89M | 2.77M | 8.79M | 6.93M |
| Cash & Short-Term Investments | 237.09K | 512.77K | 4.12M | 1.28M | 7.83M | 6.36M |
| Cash Only | 237.09K | 512.77K | 4.12M | 1.28M | 7.83M | 6.36M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 901 | 0 | 4.96K | 18.61K | 11.22K |
| Days Sales Outstanding | - | 365 | - | 106.09 | 194.71 | 302.46 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 250K | 0 | 1.48M | 621.32K | 561.03K |
| Total Non-Current Assets | 200.46K | 298.49K | 363.59K | 1.7M | 1.82M | 1.86M |
| Property, Plant & Equipment | 0 | 0 | 0 | 1.15M | 1.11M | 1.05M |
| Fixed Asset Turnover | - | - | - | 0.01x | 0.03x | 0.02x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 200.46K | 298.49K | 358.64K | 536.74K | 706.42K | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 4.95K | 12.85K | 12.85K | 851.88K |
| Total Assets | 446.38K▲ 0% | 1.1M▲ 146.9% | 6.25M▲ 467.1% | 4.46M▼ 28.6% | 10.62M▲ 137.9% | 8.79M▲ 0% |
| Asset Turnover | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Asset Growth % | - | 146.88% | 467.11% | -28.6% | 137.89% | 577.94% |
| Total Current Liabilities | 386.01K | 33.88K | 1.95M | 841.14K | 631.7K | 398.45K |
| Accounts Payable | 39.54K | 33.88K | 1.1M | 243.21K | 87.66K | 0 |
| Days Payables Outstanding | - | - | - | - | - | 124.86 |
| Short-Term Debt | 0 | 0 | 849.03K | 374K | 306.76K | 247.71K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 346.47K | 0 | 0 | 0 | 0 | 150.73K |
| Current Ratio | 0.64x | 23.71x | 3.02x | 3.29x | 13.92x | 13.92x |
| Quick Ratio | 0.64x | 23.71x | 3.02x | 3.29x | 13.92x | 13.92x |
| Cash Conversion Cycle | - | - | - | - | - | 177.6 |
| Total Non-Current Liabilities | 0 | 0 | 0 | 663.1K | 425.83K | 238.88K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 238.88K |
| Capital Lease Obligations | 0 | 0 | 0 | 663.1K | 425.83K | 1.09M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 386.01K | 33.88K | 1.95M | 1.5M | 1.06M | 637.33K |
| Total Debt | 0 | 0 | 849.03K | 1.26M | 969.86K | 486.6K |
| Net Debt | -237.09K | -512.77K | -3.27M | -22.5K | -6.86M | -5.87M |
| Debt / Equity | - | - | 0.20x | 0.43x | 0.10x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | -0.08x |
| Net Debt / EBITDA | - | - | - | - | - | 0.95x |
| Interest Coverage | - | - | - | -1.08x | -448.81x | -418.04x |
| Total Equity | 60.37K▲ 0% | 1.07M▲ 1669.4% | 4.3M▲ 302.7% | 2.96M▼ 31.2% | 9.56M▲ 223.1% | 8.15M▲ 0% |
| Equity Growth % | - | 1669.42% | 302.74% | -31.23% | 223.1% | 835.21% |
| Book Value per Share | 0.01 | 3.37 | 1.39 | 7.00 | 0.36 | 4.64 |
| Total Shareholders' Equity | 60.37K | 1.07M | 4.3M | 2.96M | 9.56M | 8.15M |
| Common Stock | 1.05K | 123 | 95 | 205 | 459 | 18 |
| Retained Earnings | -710.11K | -1.33M | -5.99M | -14.37M | -22.75M | -27.78M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
CDIO Cash Flow Statement
Cardio Diagnostics Holdings, Inc. (CDIO) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | 25.86K | -585.29K | -5.09M | -5.67M | -4.99M | -4.99M |
| Operating CF Margin % | - | -64960.16% | -535891.37% | -33238.65% | -14310.99% | - |
| Operating CF Growth % | - | -2363.39% | -769.82% | -11.42% | 11.97% | -46.37% |
| Net Income | -605.16K | -620.45K | -4.66M | -8.38M | -8.38M | -6.55M |
| Depreciation & Amortization | 10.67K | 16K | 16K | 111.62K | 276.35K | 388.42K |
| Stock-Based Compensation | 589.26K | 60K | 0 | 1.28M | 2.59M | 30.61K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | -3.28K | 112.53K | 1.1M | 0 | 77.95K |
| Working Capital Changes | 31.09K | -37.56K | -558.52K | 208.81K | 522.84K | 297.84K |
| Change in Receivables | 0 | -901 | 0 | -4.96K | -13.65K | 2.88K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 136.35K | 0 | 0 | 55.41K |
| Cash from Investing | -29.91K | -364.03K | -368K | -794.29K | -404.19K | -395.56K |
| Capital Expenditures | -29.91K | -114.03K | -76.15K | -597.01K | -214.76K | -353.94K |
| CapEx % of Revenue | - | 12655.83% | 8016.21% | 3498.48% | 615.55% | - |
| Acquisitions | 0 | -250K | 141.49K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -433.33K | -197.28K | -189.43K | -41.63K |
| Cash from Financing | 240K | 1.23M | 9.06M | 3.63M | 11.94M | 10.53M |
| Debt Issued (Net) | 0 | 0 | -188.67K | 4.5M | 0 | -268.42K |
| Equity Issued (Net) | 0 | 1000K | 1000K | 0 | 1000K | 2.12M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 240K | 105K | -2.73M | -867.53K | -605.69K | -115.04K |
| Net Change in Cash | 235.95K▲ 0% | 275.68K▲ 16.8% | 3.6M▲ 1207.6% | -2.83M▼ 178.6% | 6.54M▲ 330.9% | 4.37M▲ 0% |
| Free Cash Flow | -4.05K▲ 0% | -699.32K▼ 17162.9% | -5.09M▼ 628.0% | -6.47M▼ 27.0% | -5.4M▲ 16.5% | -5.99M▲ 0% |
| FCF Margin % | - | -77615.98% | -535891.58% | -37893.15% | -15469.46% | -37953.72% |
| FCF Growth % | - | -17162.9% | -627.99% | -27.02% | 16.53% | 0.88% |
| FCF per Share | -0.00 | -2.20 | -1.65 | -15.29 | -0.20 | -0.20 |
| FCF Conversion (FCF/Net Income) | -0.04x | 0.94x | 1.09x | 0.68x | 0.60x | 0.91x |
| Interest Paid | 0 | 0 | 0 | 30.49K | 18.64K | 4.69K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
CDIO Key Ratios
Cardio Diagnostics Holdings, Inc. (CDIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -109.96% | -173.6% | -230.77% | -133.96% | -80.38% |
| Return on Invested Capital (ROIC) | -245.81% | -429.49% | -273.72% | -222.66% | -222.66% |
| Gross Margin | 100% | 100% | 100% | 100% | -1032.5% |
| Net Margin | -68862.15% | -490630% | -49087.81% | -24028.24% | -41516.33% |
| Debt / Equity | - | 0.20x | 0.43x | 0.10x | 0.10x |
| Interest Coverage | - | - | -1.08x | -448.81x | -418.04x |
| FCF Conversion | 0.94x | 1.09x | 0.68x | 0.60x | 0.91x |
| Revenue Growth | - | 5.44% | 1696.32% | 104.45% | -55.78% |
CDIO Frequently Asked Questions
Cardio Diagnostics Holdings, Inc. (CDIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cardio Diagnostics Holdings, Inc. (CDIO) reported $0.0M in revenue for fiscal year 2024.
Cardio Diagnostics Holdings, Inc. (CDIO) grew revenue by 104.5% over the past year. This is strong growth.
Cardio Diagnostics Holdings, Inc. (CDIO) reported a net loss of $6.6M for fiscal year 2024.
Dividend & Returns
Cardio Diagnostics Holdings, Inc. (CDIO) has a return on equity (ROE) of -134.0%. Negative ROE indicates the company is unprofitable.
Cardio Diagnostics Holdings, Inc. (CDIO) had negative free cash flow of $6.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More CDIO
Cardio Diagnostics Holdings, Inc. (CDIO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates